Benzinga · Mar 9, 2026
NASDAQ · BFRI
Biofrontera Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.48
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 9:27 PM
SID Score
6.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.35M
- P/E ratio
- -0.45
- Dividend yield
- 0.00%
- 52-week range
- $0.55 – $1.52
- Volume
- 446.34K
- Avg. volume
- 135.6K
Price performance
BFRI price history
1M range · 21 trading sessions · Daily adjusted prices
BFRI closed at $1.48 after 21 trading sessions, up 35.78% for the selected period.
- Last close
- $1.48
- Period change
- +35.78%
- Period low
- $1.05
- Period high
- $1.48
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $1.48 | $1.52 | $1.4406 | $1.48 | 446.34K |
| Aug 20, 2026 | $1.43 | $1.50 | $1.40 | $1.48 | 526.13K |
| Aug 19, 2026 | $1.46 | $1.50 | $1.39 | $1.42 | 697.43K |
| Aug 18, 2026 | $1.39 | $1.495 | $1.38 | $1.44 | 1.06M |
| Aug 17, 2026 | $1.36 | $1.3999 | $1.31 | $1.35 | 762.86K |
| Aug 14, 2026 | $1.28 | $1.40 | $1.26 | $1.30 | 976.25K |
| Aug 13, 2026 | $1.27 | $1.40 | $1.2222 | $1.26 | 1.09M |
| Aug 12, 2026 | $1.22 | $1.26 | $1.20 | $1.25 | 258.41K |
| Aug 11, 2026 | $1.22 | $1.24 | $1.18 | $1.22 | 337.8K |
| Aug 10, 2026 | $1.25 | $1.27 | $1.21 | $1.21 | 441.84K |
| Aug 7, 2026 | $1.27 | $1.27 | $1.23 | $1.27 | 248.67K |
| Aug 6, 2026 | $1.25 | $1.27 | $1.21 | $1.25 | 278.69K |
| Aug 5, 2026 | $1.25 | $1.2591 | $1.21 | $1.24 | 151.12K |
| Aug 4, 2026 | $1.19 | $1.26 | $1.18 | $1.22 | 516.25K |
| Aug 3, 2026 | $1.17 | $1.25 | $1.1684 | $1.19 | 379.33K |
| Jul 31, 2026 | $1.21 | $1.2299 | $1.145 | $1.17 | 433.14K |
| Jul 30, 2026 | $1.18 | $1.27 | $1.16 | $1.23 | 796.17K |
| Jul 29, 2026 | $1.12 | $1.19 | $1.09 | $1.17 | 728.83K |
| Jul 28, 2026 | $1.05 | $1.145 | $0.995 | $1.11 | 897.91K |
| Jul 27, 2026 | $1.07 | $1.08 | $1.05 | $1.05 | 307.59K |
| Jul 24, 2026 | $1.0845 | $1.09 | $1.06 | $1.09 | 165.98K |
Latest BFRI news
The latest Smart Investors Daily articles mentioning BFRI.
Stock researchCompany · Overview
BFRI research
Overview
Company profile and research snapshot.
Company profile
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.12
- Implied upside
- —
- Analysts
- 8
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2026 | Benchmark | Speculative Buy | — |
| May 19, 2025 | Benchmark | Buy | — |
| Nov 15, 2024 | Benchmark | Buy | — |
| Aug 16, 2024 | Benchmark | Buy | — |
| Aug 31, 2023 | Benchmark | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 26, 2026
Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S. Patent Trial and
Benzinga · Feb 11, 2026
Biofrontera Application For Ameluz Usage In Basal Cell Carcinoma Treatment Received By FDA
Benzinga · Feb 11, 2026
Biofrontera's Supplemental New Drug Application For Ameluz Accepted By FDA
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (PDT), today announced that the U.S. Food and
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
